Ensifentrine
- Generic Name
- Ensifentrine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H31N5O4
- CAS Number
- 1884461-72-6
- Unique Ingredient Identifier
- 3E3D8T1GIX
- Background
Ensifentrine is under investigation in clinical trial NCT04535986 (A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Nebulized Ensifentrine in Healthy Chinese Subjects
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Nuance Pharma (shanghai) Co., Ltd
- Target Recruit Count
- 28
- Registration Number
- NCT05758428
- Locations
- 🇨🇳
The Third Hospital of Changsha, Changsha, Hunan, China
A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Nuance Pharma (shanghai) Co., Ltd
- Target Recruit Count
- 488
- Registration Number
- NCT05743075
- Locations
- 🇨🇳
1st Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Effect of Ensifentrine on Sputum Markers of Inflammation in COPD
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 50
- Registration Number
- NCT05270525
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
- Conditions
- Interventions
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 790
- Registration Number
- NCT04542057
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Clinical Trials of Florida. LLC, Miami, Florida, United States
🇺🇸Research Institute of South Florida, Miami, Florida, United States
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
- Conditions
- Interventions
- First Posted Date
- 2020-09-02
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 763
- Registration Number
- NCT04535986
- Locations
- 🇺🇸
AMR Tempe, Tempe, Arizona, United States
🇺🇸Phoenix Medical Group, Peoria, Arizona, United States
🇺🇸TPMG Clinical Research Williamsburg, Williamsburg, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.